HC Wainwright & Co. Reiterates Buy on GT Biopharma, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on GT Biopharma (NASDAQ:GTBP) and maintained a $5 price target.
August 08, 2023 | 10:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on GT Biopharma and maintained a $5 price target, which could positively impact the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of a 'Buy' rating and maintenance of a $5 price target by HC Wainwright & Co. indicates their continued confidence in GT Biopharma, which could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100